<!--
  Copyright SemanticBits, Northwestern University and Akaza Research
  
  Distributed under the OSI-approved BSD 3-Clause License.
  See http://ncip.github.com/caaers/LICENSE.txt for details.
-->
<?xml version="1.0" encoding="UTF-8"?><AE_REPORT>
    <REPORT_TYPE>Regular report</REPORT_TYPE>




    <REPORTER_INFORMATION EMAIL="reshma.koganti@gmail.com" FAX="5555555555" FIRST_NAME="mayo super" LAST_NAME="user" PHONE="5555555555"/>
    <PHYSICIAN_INFORMATION EMAIL="xx@kk.com" FIRST_NAME="x" LAST_NAME="x" PHONE="9999999999"/>
    <SUBMITTER_INFORMATION EMAIL="reshma.koganti@gmail.com" FAX="5555555555" FIRST_NAME="mayo super" LAST_NAME="user" PHONE="5555555555"/>
    <INSTITUTION_INFORMATION CTEP_ID="MN026">
        <INSTITUTION_NAME>Mayo Clinic Rochester</INSTITUTION_NAME>
    </INSTITUTION_INFORMATION>
    <PROTOCOL_INFORMATION NCI_PROTOCOL_NUMBER="8231"/>
    <TREATMENT_ASSIGNMENT_INFORMATION>
        <TREATMENT_ASSIGNMENT_CODE>A3</TREATMENT_ASSIGNMENT_CODE>
    </TREATMENT_ASSIGNMENT_INFORMATION>
    <COURSE_INFORMATION>
        <START_DATE_OF_FIRST_COURSE>2012-05-01</START_DATE_OF_FIRST_COURSE>
        <START_DATE_OF_AE_COURSE>2012-05-01</START_DATE_OF_AE_COURSE>
        <COURSE_NUMBER_OF_AE>1</COURSE_NUMBER_OF_AE>
        <TOTAL_NUMBER_OF_COURSES>1</TOTAL_NUMBER_OF_COURSES>
        <INV_AGENT_ADMIN>Yes</INV_AGENT_ADMIN>
    </COURSE_INFORMATION>
    <DESCRIPTION_OF_EVENT>
        <EVENT_DESCRIPTION>test</EVENT_DESCRIPTION>
        <PRESENT_STATUS>Intervention for AE Continues</PRESENT_STATUS>
        <RETREATED>No</RETREATED>
        <REMOVED_FROM_PROTOCOL_TRT>No</REMOVED_FROM_PROTOCOL_TRT>
    </DESCRIPTION_OF_EVENT>
    <PATIENT_INFORMATION PATIENT_ID="jj3">
        <BIRTH_DATE>1990-11</BIRTH_DATE>
        <RACE>Unknown</RACE>
        <ETHNICITY>Unknown</ETHNICITY>
        <GENDER>Unknown</GENDER>
        <HEIGHT>100.0</HEIGHT>
        <WEIGHT>100.0</WEIGHT>
        <DISEASE_NAME>Adenocarcinoma of the pancreas</DISEASE_NAME>
        <PRIMARY_SITE_OF_DISEASE>Bladder</PRIMARY_SITE_OF_DISEASE>
        <PRIMARY_ANATOMIC_SITE>Genitourinary</PRIMARY_ANATOMIC_SITE>
    </PATIENT_INFORMATION>
    <PRIOR_THERAPY>
        <THERAPY_NAME>Chemotherapy multiple agents systemic</THERAPY_NAME>
        <THERAPY_COMMENTS>test</THERAPY_COMMENTS>
    </PRIOR_THERAPY>
    <PROTOCOL_AGENT AGENT_NAME="Fluorine-18 2-Fluoro-2-deoxy-D-Glucose (18F-FDG)" NSC_NUMBER="723398">
        <TOTAL_DOSE_ADMINISTERED>1</TOTAL_DOSE_ADMINISTERED>
        <LAST_ADMINISTERED_DATE>2012-05-01</LAST_ADMINISTERED_DATE>
        <DOSE_UOM>BVP</DOSE_UOM>
        <AGENT_DELAYED>No</AGENT_DELAYED>
    </PROTOCOL_AGENT>
    <PROTOCOL_AGENT AGENT_NAME="OSI-774 (erlotinib; Tarceva)" NSC_NUMBER="718781">
        <TOTAL_DOSE_ADMINISTERED>1</TOTAL_DOSE_ADMINISTERED>
        <LAST_ADMINISTERED_DATE>2012-05-10</LAST_ADMINISTERED_DATE>
        <DOSE_UOM>cells</DOSE_UOM>
        <AGENT_ADJUSTMENT>Dose reduced</AGENT_ADJUSTMENT>
        <AGENT_DELAYED>No</AGENT_DELAYED>
    </PROTOCOL_AGENT>
    <ADVERSE_EVENT_CTC GRADE="3">
        <IS_PRIMARY_AE>Yes</IS_PRIMARY_AE>
        <CATEGORY>Vascular disorders</CATEGORY>
        <AE_TERM>Vasculitis</AE_TERM>
        <AE_START_DATE>2012-05-01</AE_START_DATE>
        <HOSPITALIZATION>Yes</HOSPITALIZATION>
        <AE_COMMENTS>test</AE_COMMENTS>
        <ATTRIBUTION_FOR_AE>
            <CAUSE_NAME>Fluorine-18 2-Fluoro-2-deoxy-D-Glucose (18F-FDG)</CAUSE_NAME>
            <TYPE_OF_CAUSE>AGENT</TYPE_OF_CAUSE>
            <ATTRIBUTION>Possible</ATTRIBUTION>
        </ATTRIBUTION_FOR_AE>
        <ATTRIBUTION_FOR_AE>
            <CAUSE_NAME>OSI-774 (erlotinib; Tarceva)</CAUSE_NAME>
            <TYPE_OF_CAUSE>AGENT</TYPE_OF_CAUSE>
            <ATTRIBUTION>Possible</ATTRIBUTION>
        </ATTRIBUTION_FOR_AE>
        <ATTRIBUTION_FOR_AE>
            <CAUSE_NAME>Adenocarcinoma of the pancreas</CAUSE_NAME>
            <TYPE_OF_CAUSE>DISEASE</TYPE_OF_CAUSE>
            <ATTRIBUTION>Unlikely</ATTRIBUTION>
        </ATTRIBUTION_FOR_AE>
    </ADVERSE_EVENT_CTC>
    <ADVERSE_EVENT_CTC GRADE="3">
        <IS_PRIMARY_AE>No</IS_PRIMARY_AE>
        <CATEGORY>Eye disorders</CATEGORY>
        <AE_TERM>Retinal tear</AE_TERM>
        <AE_START_DATE>2012-05-01</AE_START_DATE>
        <HOSPITALIZATION>Yes</HOSPITALIZATION>
        <AE_COMMENTS>ja</AE_COMMENTS>
        <ATTRIBUTION_FOR_AE>
            <CAUSE_NAME>Fluorine-18 2-Fluoro-2-deoxy-D-Glucose (18F-FDG)</CAUSE_NAME>
            <TYPE_OF_CAUSE>AGENT</TYPE_OF_CAUSE>
            <ATTRIBUTION>Probable</ATTRIBUTION>
        </ATTRIBUTION_FOR_AE>
        <ATTRIBUTION_FOR_AE>
            <CAUSE_NAME>OSI-774 (erlotinib; Tarceva)</CAUSE_NAME>
            <TYPE_OF_CAUSE>AGENT</TYPE_OF_CAUSE>
            <ATTRIBUTION>Possible</ATTRIBUTION>
        </ATTRIBUTION_FOR_AE>
        <ATTRIBUTION_FOR_AE>
            <CAUSE_NAME>Adenocarcinoma of the pancreas</CAUSE_NAME>
            <TYPE_OF_CAUSE>DISEASE</TYPE_OF_CAUSE>
            <ATTRIBUTION>Possible</ATTRIBUTION>
        </ATTRIBUTION_FOR_AE>
    </ADVERSE_EVENT_CTC>
</AE_REPORT>
